Clinical Trial Update: Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on trametinib for relapsed or refractory Juvenile Myelomonocytic Leukemia (JMML), including patients with Neurofibromatosis Type…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Myelomonocytic Leukemia
• Neurofibromatosis Type

Drugs mentioned

• Trametinib (trametinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Juvenile Myelomonocytic Leukemia, Neurofibromatosis Type 1 | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-07-16